Search

Your search keyword '"Cirioni, Oscar"' showing total 387 results
Start Over Author "Cirioni, Oscar" Language english
387 results on '"Cirioni, Oscar"'

1. ER-mitochondria association negatively affects wound healing by regulating NLRP3 activation

Author

Licini, Caterina, Morroni, Gianluca, Lucarini, Guendalina, Vitto, Veronica Angela Maria, Orlando, Fiorenza, Missiroli, Sonia, D’Achille, Gloria, Perrone, Mariasole, Spadoni, Tatiana, Graciotti, Laura, Bigossi, Giorgia, Provinciali, Mauro, Offidani, Annamaria, Mattioli-Belmonte, Monica, Cirioni, Oscar, Pinton, Paolo, Simonetti, Oriana, and Marchi, Saverio

Published
2024
Full Text
View/download PDF

22. Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.

Author

Rizzetto, Giulio, Gambini, Daisy, Maurizi, Andrea, Candelora, Matteo, Molinelli, Elisa, Cirioni, Oscar, Brescini, Lucia, Giacometti, Andrea, Offidani, Annamaria, and Simonetti, Oriana

Subjects
ANTIMICROBIAL peptides, GRAM-negative bacteria, DRUG resistance in bacteria, FUNGI, ANTIFUNGAL agents, ANTIBIOTICS
Abstract

Antibiotic resistance is rapidly increasing, and new anti-infective therapies are urgently needed. In this regard, antimicrobial peptides (AMPs) may represent potential candidates for the treatment of infections caused by multiresistant microorganisms. In this narrative review, we reported the experience of our research group over 20 years. We described the AMPs we evaluated against Gram-positive, Gram-negative, and fungi. In conclusion, our experience shows that AMPs can be a key option for treating multiresistant infections and overcoming resistance mechanisms. The combination of AMPs allows antibiotics and antifungals that are no longer effective to exploit the synergistic effect by restoring their efficacy. A current limitation includes poor data on human patients, the cost of some AMPs, and their safety, which is why studies on humans are needed as soon as possible. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. MRSA and Skin Infections in Psoriatic Patients: Therapeutic Options and New Perspectives.

Author

Rizzetto, Giulio, Molinelli, Elisa, Radi, Giulia, Cirioni, Oscar, Brescini, Lucia, Giacometti, Andrea, Offidani, Annamaria, and Simonetti, Oriana

Subjects
SKIN infections, VITAMIN E, METHICILLIN-resistant staphylococcus aureus, STAPHYLOCOCCAL diseases, DRUG resistance in bacteria, QUORUM sensing
Abstract

Psoriatic patients present various infectious risk factors, but there are few studies in the literature evaluating the actual impact of psoriasis in severe staphylococcal skin infections. Our narrative review of the literature suggests that psoriatic patients are at increased risk of both colonization and severe infection, during hospitalization, by S. aureus. The latter also appears to play a role in the pathogenesis of psoriasis through the production of exotoxins. Hospitalized psoriatic patients are also at increased risk of MRSA skin infections. For this reason, new molecules are needed that could both overcome bacterial resistance and inhibit exotoxin production. In our opinion, in the near future, topical quorum sensing inhibitors in combination with current anti-MRSA therapies will be able to overcome the increasing resistance and block exotoxin production. Supplementation with Vitamin E (VE) or derivatives could also enhance the effect of anti-MRSA antibiotics, considering that psoriatic patients with metabolic comorbidities show a low intake of VE and low serum levels, making VE supplementation an interesting new perspective. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

24. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization

Author

Simonetti,Oriana, Rizzetto,Giulio, Molinelli,Elisa, Cirioni,Oscar, and Offidani,Annamaria

Subjects
Therapeutics and Clinical Risk Management
Abstract

Oriana Simonetti,1,* Giulio Rizzetto,1,* Elisa Molinelli,1 Oscar Cirioni,2 Annamaria Offidani1 1Clinic of Dermatology, Department of Clinical and Molecular Sciences, Polytechnic University of Marche, Ancona, Italy; 2Clinic of Infectious Diseases, Department of Biomedical Sciences and Public Health, Polytechnic University of Marche, Ancona, Italy*These authors contributed equally to this workCorrespondence: Oriana SimonettiDermatological Unit, Department of Clinical and Molecular Sciences, Polytechnic Marche University, Via Conca 71, Ancona, 60126, ItalyEmail o.simonetti@staff.univpm.itIntroduction: Dalbavancin is a bactericidal lipoglycopeptide active against gram-positives. Its use has been approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI).Methods: We conducted a narrative review of the literature on the safety profile of dalbavancin. The bibliographic research was carried out on the PubMed database on 6 November 2020 by seeking combinations of the following keywords: dalbavancin, adverse effects, safety, drug interactions, and skin infections.Results: Five double-blind Phase 3 randomized clinical trials, 2 open-label randomized trials, and 4 retrospective studies were identified. No statistically significant differences were found between dalbavancin and comparators in the incidence of adverse events. Retrospective studies confirm the low incidence of adverse events.Conclusion: Dalbavancin is a therapeutic option that has demonstrated an excellent safety profile, also in relation to the other MRSA therapies available. Its use represents a cost-effective solution for the treatment of those patients with ABSSSI who would need hospitalization. One limitation of this study is that most of the available data are from Phase III clinical trials. Further real-life studies with a larger sample size are therefore needed to better assess the safety profile of the dalbavancin, especially to investigate the true incidence of rare adverse events.Keywords: dalbavancin, adverse events, safety, skin infections, ABSSSI

Published
2021

29. Relationship Between Health-Related Quality of Life Measures and High HIV Viral Load in HIV-Infected Triple-Class-Experienced Patients

Author

Bucciardini, Raffaella, Pugliese, Katherina, Weimer, Liliana, Digregorio, Massimiliano, Fragola, Vincenzo, Mancini, Mariagrazia, Maroccia, Zaira, Ladisa, Nicoletta, Francisci, Daniela, Bellagamba, Rita, Antoni, Anna Degli, Guaraldi, Giovanni, Cirioni, Oscar, Ortu, Francesco, Parruti, Giustino, Mannazzu, Marco, Libertone, Raffaella, Donnini, Stefania, and Floridia, Marco

Published
2014

31. In Vitro Activity of Novel Lipopeptides against Triazole-Resistant Aspergillus fumigatus.

Author

Fioriti, Simona, Cirioni, Oscar, Simonetti, Oriana, Franca, Lucia, Candelaresi, Bianca, Pallotta, Francesco, Neubauer, Damian, Kamysz, Elzbieta, Kamysz, Wojciech, Canovari, Benedetta, Brescini, Lucia, Morroni, Gianluca, and Barchiesi, Francesco

Subjects
*ASPERGILLUS fumigatus, *ANTIFUNGAL agents, *PULMONARY aspergillosis, *MICROSCOPY, *DRUG resistance, *ANTIMICROBIAL peptides, *ASPERGILLOSIS, *MYCOSES
Abstract

Aspergillosis, which is mainly sustained by Aspergillus fumigatus, includes a broad spectrum of diseases. They are usually severe in patients with co-morbidities. The first-line therapy includes triazoles, for which an increasing incidence of drug resistance has been lately described. As a consequence of this, the need for new and alternative antifungal molecules is absolutely necessary. As peptides represent promising antimicrobial molecules, two lipopeptides (C14-NleRR-NH2, C14-WRR-NH2) were tested to assess the antifungal activity against azole-resistant A. fumigatus. Antifungal activity was evaluated by determination of minimum inhibitory concentrations (MICs), time–kill curves, XTT assay, optical microscopy, and checkerboard combination with isavuconazole. Both lipopeptides showed antifungal activity, with MICs ranging from 8 mg/L to 16 mg/L, and a dose-dependent effect was confirmed by both time–kill curves and XTT assays. Microscopy showed that hyphae growth was hampered at concentrations equal to or higher than MICs. The rising antifungal resistance highlights the usefulness of novel compounds to treat severe fungal infections. Although further studies assessing the activity of lipopeptides are necessary, these molecules could be effective antifungal alternatives that overcome the current resistances. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

37. Role of Daptomycin in Cutaneous Wound Healing: A Narrative Review.

Author

Rizzetto, Giulio, Molinelli, Elisa, Radi, Giulia, Diotallevi, Federico, Cirioni, Oscar, Brescini, Lucia, Giacometti, Andrea, Offidani, Annamaria, and Simonetti, Oriana

Subjects
WOUND healing, DAPTOMYCIN, SKIN injuries, METHICILLIN-resistant staphylococcus aureus, VITAMIN E
Abstract

Daptomycin is active against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and the on-label indications for its use include complicated skin and skin structure infections (cSSSI). We performed a narrative review of the literature with the aim to evaluate the role of daptomycin in the skin wound healing process, proposing our point of view on the possible association with other molecules that could improve the skin healing process. Daptomycin may improve wound healing in MRSA-infected burns, surgical wounds, and diabetic feet, but further studies in humans with histological examination are needed. In the future, the combination of daptomycin with other molecules with synergistic action, such as vitamin E and derivates, IB-367, RNA III-inhibiting peptide (RIP), and palladium nanoflowers, may help to improve wound healing and overcome forms of antibiotic resistance. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results